Top

International Journal of Colorectal Disease

Published in:

01-05-2020 | Metformin | Original Article

Effect of metformin on the mortality of colorectal cancer patients with T2DM: meta-analysis of sex differences

Authors: Yunzi Wang, Jingping Xiao, Yuanyu Zhao, Shijuan Du, Jiang Du

Published in: International Journal of Colorectal Disease | Issue 5/2020

Abstract

Purpose

To evaluate the effect of metformin as a treatment for the mortality of colorectal cancer (CRC) patients with type 2 diabetes mellitus (T2DM).

Methods

We searched Medline, PubMed, EMBASE, Clinical Trials.gov (http://www.clinicaltrials.gov), and the Cochrane Collaboration Library from inception to November 2019. To analyze the relationship between metformin and the overall mortality, specific mortality, and sex differences in CRC patients with T2DM, hazard ratios (HRs) with 95% confidence intervals (CIs) were used. Egger’s test and Begg’s test were used to assess publication bias.

Results

We included 8 cohort studies in our meta-analysis. CRC patients with T2DM treated with metformin had a lower overall mortality than CRC patients with T2DM who did not receive metformin (HR = 0.80, 95% CI 0.67–0.95). There was no significant difference in CRC-specific mortality between CRC patients with T2DM who used metformin and those who did not (HR = 0.84, 95% CI 0.65–1.08). However, females had a lower CRC-specific mortality among CRC patients with T2DM than males (HR = 0.63, 95% CI 0.41–0.97).

Conclusion

Metformin reduced the overall mortality of CRC patients with T2DM. Moreover, female CRC patients with T2DM using metformin had lower CRC-specific mortality than male CRC patients with T2DM.

Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68(1):7–30. https://doi.org/10.3322/caac.21442 CrossRefPubMed

Abdelsatir AA, Husain NE, Hassan AT, Elmadhoun WM, Almobarak AO, Ahmed MH (2015) Potential benefit of metformin as treatment for colon cancer: the evidence so far. Asian Pacific journal of cancer prevention : APJCP 16(18):8053–8058. https://doi.org/10.7314/apjcp.2015.16.18.8053 CrossRefPubMed

Mills KT, Bellows CF, Hoffman AE, Kelly TN, Gagliardi G (2013) Diabetes mellitus and colorectal cancer prognosis: a meta-analysis. Dis Colon rectum 56(11):1304–1319. https://doi.org/10.1097/DCR.0b013e3182a479f9 CrossRefPubMedPubMedCentral

Miranda VC, Barroso-Sousa R, Glasberg J, Riechelmann RP (2014) Exploring the role of metformin in anticancer treatments: a systematic review. Drugs of today 50(9):623–640. https://doi.org/10.1358/dot.2014.50.9.2229920 CrossRefPubMed

Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B, American Diabetes A, European Association for Study of D (2009) Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32(1):193–203. https://doi.org/10.2337/dc08-9025 CrossRefPubMedPubMedCentral

Queiroz EA, Puukila S, Eichler R, Sampaio SC, Forsyth HL, Lees SJ, Barbosa AM, Dekker RF, Fortes ZB, Khaper N (2014) Metformin induces apoptosis and cell cycle arrest mediated by oxidative stress, AMPK and FOXO3a in MCF-7 breast cancer cells. PLoS One 9(5):e98207. https://doi.org/10.1371/journal.pone.0098207 CrossRefPubMedPubMedCentral

Feng Y, Ke C, Tang Q, Dong H, Zheng X, Lin W, Ke J, Huang J, Yeung SC, Zhang H (2014) Metformin promotes autophagy and apoptosis in esophageal squamous cell carcinoma by downregulating Stat3 signaling. Cell Death Dis 5:e1088. https://doi.org/10.1038/cddis.2014.59 CrossRefPubMedPubMedCentral

Fransgaard T, Thygesen LC, Gogenur I (2016) Metformin increases overall survival in patients with diabetes undergoing surgery for colorectal cancer. Ann Surg Oncol 23(5):1569–1575. https://doi.org/10.1245/s10434-015-5028-8 CrossRefPubMed

Mc Menamin UC, Murray LJ, Hughes CM, Cardwell CR (2016) Metformin use and survival after colorectal cancer: a population-based cohort study. Int J Cancer 138(2):369–379. https://doi.org/10.1002/ijc.29720 CrossRefPubMed

10.

Fransgaard T, Thygesen LC, Gogenur I (2018) Association between metformin use after surgery for colorectal cancer and oncological outcomes: a nationwide register-based study. Int J Cancer 143(1):63–72. https://doi.org/10.1002/ijc.31305 CrossRefPubMed

11.

Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25(9):603–605. https://doi.org/10.1007/s10654-010-9491-z CrossRefPubMed

12.

Lee JH, Kim TI, Jeon SM, Hong SP, Cheon JH, Kim WH (2012) The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus. Int J Cancer 131(3):752–759. https://doi.org/10.1002/ijc.26421 CrossRefPubMed

13.

Zanders MM, van Herk-Sukel MP, Vissers PA, Herings RM, Haak HR, van de Poll-Franse LV (2015) Are metformin, statin and aspirin use still associated with overall mortality among colorectal cancer patients with diabetes if adjusted for one another? Br J Cancer 113(3):403–410. https://doi.org/10.1038/bjc.2015.259 CrossRefPubMedPubMedCentral

14.

Park JW, Lee JH, Park YH, Park SJ, Cheon JH, Kim WH, Kim TI (2017) Sex-dependent difference in the effect of metformin on colorectal cancer-specific mortality of diabetic colorectal cancer patients. World J Gastroenterol 23(28):5196–5205. https://doi.org/10.3748/wjg.v23.i28.5196 CrossRefPubMedPubMedCentral

15.

Zhu RC, Rattanakorn K, Pham S, Mallam D, Mcintyre T, Salifu MO, Youssef I, McFarlane SI, Vignesh S (2017) Survival benefits in colorectal adenocarcinoma with the use of metformin among a black diabetic inner city population. Colorectal cancer 6(1):33–41. https://doi.org/10.2217/crc-2017-0001 CrossRefPubMedPubMedCentral

16.

Ki YJ, Kim HJ, Kim MS, Park CM, Ko MJ, Seo YS, Moon SM, Choi JA (2017) Association between metformin use and survival in nonmetastatic rectal Cancer treated with a curative resection: a Nationwide population study. Cancer research and treatment : official journal of Korean Cancer Association 49(1):29–36. https://doi.org/10.4143/crt.2016.128 CrossRef

17.

Krishan S, Richardson DR, Sahni S (2015) Adenosine monophosphate-activated kinase and its key role in catabolism: structure, regulation, biological activity, and pharmacological activation. Mol Pharmacol 87(3):363–377. https://doi.org/10.1124/mol.114.095810 CrossRefPubMed

18.

Kwan HT, Chan DW, Cai PC, Mak CS, Yung MM, Leung TH, Wong OG, Cheung AN, Ngan HY (2013) AMPK activators suppress cervical cancer cell growth through inhibition of DVL3 mediated Wnt/beta-catenin signaling activity. PLoS One 8(1):e53597. https://doi.org/10.1371/journal.pone.0053597 CrossRefPubMedPubMedCentral

19.

Tan BK, Adya R, Chen J, Lehnert H, Sant Cassia LJ, Randeva HS (2011) Metformin treatment exerts antiinvasive and antimetastatic effects in human endometrial carcinoma cells. J Clin Endocrinol Metab 96(3):808–816. https://doi.org/10.1210/jc.2010-1803 CrossRefPubMed

20.

Kalender A, Selvaraj A, Kim SY, Gulati P, Brule S, Viollet B, Kemp BE, Bardeesy N, Dennis P, Schlager JJ, Marette A, Kozma SC, Thomas G (2010) Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab 11(5):390–401. https://doi.org/10.1016/j.cmet.2010.03.014 CrossRefPubMedPubMedCentral

21.

Ben Sahra I, Regazzetti C, Robert G, Laurent K, Le Marchand-Brustel Y, Auberger P, Tanti JF, Giorgetti-Peraldi S, Bost F (2011) Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res 71(13):4366–4372. https://doi.org/10.1158/0008-5472.CAN-10-1769 CrossRefPubMed

22.

Vakana E, Altman JK, Glaser H, Donato NJ, Platanias LC (2011) Antileukemic effects of AMPK activators on BCR-ABL-expressing cells. Blood 118(24):6399–6402. https://doi.org/10.1182/blood-2011-01-332783 CrossRefPubMedPubMedCentral

23.

Ma J, Sawai H, Matsuo Y, Ochi N, Yasuda A, Takahashi H, Wakasugi T, Funahashi H, Sato M, Takeyama H (2010) IGF-1 mediates PTEN suppression and enhances cell invasion and proliferation via activation of the IGF-1/PI3K/Akt signaling pathway in pancreatic cancer cells. J Surg Res 160(1):90–101. https://doi.org/10.1016/j.jss.2008.08.016 CrossRefPubMed

24.

Higurashi T, Takahashi H, Endo H, Hosono K, Yamada E, Ohkubo H, Sakai E, Uchiyama T, Hata Y, Fujisawa N, Uchiyama S, Ezuka A, Nagase H, Kessoku T, Matsuhashi N, Yamanaka S, Inayama Y, Morita S, Nakajima A (2012) Metformin efficacy and safety for colorectal polyps: a double-blind randomized controlled trial. BMC Cancer 12:118. https://doi.org/10.1186/1471-2407-12-118 CrossRefPubMedPubMedCentral

25.

Orecchioni S, Reggiani F, Talarico G, Mancuso P, Calleri A, Gregato G, Labanca V, Noonan DM, Dallaglio K, Albini A, Bertolini F (2015) The biguanides metformin and phenformin inhibit angiogenesis, local and metastatic growth of breast cancer by targeting both neoplastic and microenvironment cells. Int J Cancer 136(6):E534–E544. https://doi.org/10.1002/ijc.29193 CrossRefPubMed

26.

Kim HG, Hien TT, Han EH, Hwang YP, Choi JH, Kang KW, Kwon KI, Kim BH, Kim SK, Song GY, Jeong TC, Jeong HG (2011) Metformin inhibits P-glycoprotein expression via the NF-kappaB pathway and CRE transcriptional activity through AMPK activation. Br J Pharmacol 162(5):1096–1108. https://doi.org/10.1111/j.1476-5381.2010.01101.x CrossRefPubMedPubMedCentral

27.

Cossor FI, Adams-Campbell LL, Chlebowski RT, Gunter MJ, Johnson K, Martell RE, McTiernan A, Simon MS, Rohan T, Wallace RB, Paulus JK (2013) Diabetes, metformin use, and colorectal cancer survival in postmenopausal women. Cancer Epidemiol 37(5):742–749. https://doi.org/10.1016/j.canep.2013.04.015 CrossRefPubMedPubMedCentral

28.

Lee MS, Hsu CC, Wahlqvist ML, Tsai HN, Chang YH, Huang YC (2011) Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC Cancer 11:20. https://doi.org/10.1186/1471-2407-11-20 CrossRefPubMedPubMedCentral

Title: Effect of metformin on the mortality of colorectal cancer patients with T2DM: meta-analysis of sex differences
Authors: Yunzi Wang
Jingping Xiao
Yuanyu Zhao
Shijuan Du
Jiang Du
Publication date: 01-05-2020
Publisher: Springer Berlin Heidelberg
Keywords: Metformin
Colorectal Cancer
Colorectal Cancer
Published in: International Journal of Colorectal Disease / Issue 5/2020
Print ISSN: 0179-1958
Electronic ISSN: 1432-1262
DOI: https://doi.org/10.1007/s00384-020-03539-5

At a glance: The STEP trials

Springer Medicine

Effect of metformin on the mortality of colorectal cancer patients with T2DM: meta-analysis of sex differences

Abstract

Purpose

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 5/2020

Nomogram predicting cancer-specific mortality in early-onset rectal cancer: a competing risk analysis

The efficacy of tumor characterization and tumor detectability of linked color imaging and blue laser imaging with an LED endoscope compared to a LASER endoscope

High prevalence of asymptomatic internal hernias after laparoscopic anterior resection in a retrospective analysis of postoperative computed tomography

What factors determine specimen quality in colon cancer surgery? A cohort study

Prevention of anastomotic leak in rectal cancer surgery with local antibiotic decontamination: a prospective, randomized, double-blind, placebo-controlled single center trial

Factors related to short-term outcomes and delayed systemic treatment following primary tumor resection for asymptomatic stage IV colorectal cancer